- Home
- Media Center
- Press releases
- Medical technologies
Medical technologies
Long-Term ERLEADA® (apalutamide) Patient-Reported Outcomes Data in Metastatic Castration-Sensitive Prostate Cancer Demonstrate Maintenance of Health-Related Quality of Life for Patients
Results at ASCO from Phase 3 TITAN study final analysis confirm survival benefit achieved with the addition of ERLEADA® to androgen deprivation therapy without significant side effect burden
RYBREVANTTM (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
RYBREVANTTM is the first fully-human, bispecific antibody approved in lung cancer Simultaneous FDA approval of a companion diagnostic aids in the identification of exon 20 insertion mutations
New Amivantamab Data from CHRYSALIS Study Show Robust Clinical Activity and Durable Responses in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Mutations
Data presented have been submitted to U.S. and EU regulatory agencies and represent an important step towards addressing the high unmet need in this patient population
Updated Results from the Phase 1 Study of the BCMAxCD3 Bispecific Teclistamab Show Preliminary Efficacy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
First-reported results for the subcutaneous formulation and updated results for the intravenous formulation presented at ASH 2020
Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple Myeloma
Combined results from Phase 1b/2 CARTITUDE-1 study presented at ASH 2020 show 97 percent overall response rate at median follow-up of 12.4 months
ERLEADA® (apalutamide) Significantly Improved Overall Survival in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Final analysis of the Phase 3 SPARTAN study presented during ASCO Virtual Scientific Program suggests 14-month improvement in median overall survival
Biosense Webster Unveils Late-Breaking Results from PRECEPT Study in Patients with Persistent Atrial Fibrillation
PRECEPT study demonstrated 15-month freedom from symptomatic persistent atrial fibrillation in 80.4 percent of patients who underwent cardiac ablation using THERMOCOOL SMARTTOUCH® SF Catheter1
Ethicon Launches VISTASEAL Fibrin Sealant (Human) to Manage Bleeding During Surgery
Next Generation Device Simplifies Setup and May Save Valuable Operating Room Time VISTASEAL is first innovation to emerge from Ethicon’s strategic partnership with Grifols, a pioneer in the plasma industry